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Abstract
Background: Some strains of Bacteroides fragilis species are associated with diarrhea as a result of enterotoxin
production (bft or fragilysin). Fragilysin is activated by C11 protease (fpn) and together with C10 protease (bfp) play
a significant role in its invasiveness. The objectives of this study were to investigate the proportion of clinical isolates
from extra-intestinal sources that are toxin producers and characterize the genes mediating toxin production. Clinical
isolates submitted to our reference laboratory over the last 13 years were screened for toxin production using PCR
technique. All stool isolates were excluded. The isolates were tested for their susceptibility to 8 antimicrobial agents by
E test. Carbapenem resistance gene cfiA was detected by PCR.
Results: A total of 421 B. fragilis isolates were viable. Out of these, bft was detected in 210 (49.9%) isolates. Of the 210
bft-positive isolates, 171 (81.4%), 33 (15.7%) and 6 (2.8%) harbored bft-1, bft-2, and bft-3 genes, respectively. Twenty
(9.5%) of the bft-positive strains originated from bloodstream infections. Twenty-five, 20 and 9 strains harbored bfp-1,
bfp-2 and bfp-3 gene, respectively. Two, 3, 4 bfp isotypes were detected simultaneously in some of strains.
The resistance rates against amoxicillin-clavulanic acid was 32%, clindamycin 62%, cefoxitin 26%, imipenem
11%, meropenem 17%, metronidazole 4%, piperacillin 61% and tigecycline 14%. A chromosomally located cfiA
gene that encode metallo-β-lactamase was identified in only 34 isolates (16.2%).
Conclusions: The prevalence of enterotoxin-producing B. fragilis was high among the extra-intestinal isolates.
Metronidazole was the most active agent against all isolates. There was no statistically significance difference
between resistance rates among bft-positive and bft-negative isolates except for clindamycin.
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Backgrounds
Bacteroides species are obligate anaerobic members of
the normal microbiota of the human gut. They are the
commonest anaerobic bacteria associated with clinical
infections particularly those associated with infections of
the mucous membranes and adjacent tissues [1]. B.
fragilis is a type species of the Bacteroides genus whose
numerical population is far less than the other
Bacteroides spp., (e.g. B. thetaiotaomicron, B. distasonis
and B. vulgatus), in the normal gut microbiota. However,
paradoxically, it is the most common non-spore forming
anaerobic bacteria found in routine clinical specimens,
e.g. those obtained from deep intra-abdominal abscesses,
suppurative skin and soft tissue infections, infections fol-
lowing intra-abdominal and vaginal post-hysterectomy
surgeries [1]. Recent studies on gut microbiota have
suggested that B. fragilis can be the dominant species
associated/adherent to the colonic mucosa in healthy
individuals [2] contrary to the old believe that its
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contribution to the anaerobic microbiota of the gut is
minimal based on studies on fecal samples.
An important virulence factor of B. fragilis is an en-
terotoxin. Enterotoxin-producing B. fragilis (ETBF)
strain was first isolated from the stool of neonatal lambs
with diarrhea in 1984 [3]. ETBF was later found to cause
diarrhea in humans and has been defined as one of the 6
possible causes of diarrhea in children aged 1–5 years
[4]. It has also been isolated infrequently from stool
specimens of symptomatic adult patients [5]. Although
some reports have put the prevalence of extra-intestinal
ETBF at 6.2–38% [6, 7], the prevalence of ETBF strains
among B. fragilis isolates from diarrheagenic and extra-
intestinal clinical samples in Kuwait is unknown. The
enterotoxin produced by B. fragilis is also known as
fragilysin. It is a zinc-dependent, non-lethal, heat labile
metalloprotease of about 20 kDa [8] which acts by cleav-
ing the E-cadherin protein of zonula adherens and tight
junctions in the intestinal epithelial cells leading to re-
arrangement of the actin of the cytoskeleton of the epi-
thelial cells [9, 10]. So far the gene mediating fragilysin
(bft) has been well characterized into 4 isotypes, namely
bft-1, bft-2, bft-3 and bft-4 [11]; the latter is mainly
found in the Far East [7].
In addition, B. fragilis has another virulence factor, an
endotoxin/lipopolysaccharide (LPS) with a demonstrable
toxicity [12]. Once B. fragilis is exposed to antibiotics, it
liberates endotoxin more than other Bacteroides species
which may explain why this species is associated with
clinical infections and higher mortality rate [13].
Some studies have demonstrated an association be-
tween increased prevalence of ETBF strains and inflam-
matory bowel diseases, such as Crohn’s disease and
ulcerative colitis [14], while a possible pathogenic role in
the etiology of colorectal cancer [15] and bacteremia
[16, 17] has been suggested. Two cystein peptidase types
with pathogenic role have recently been described: bfp1–
4 genes encoding C10 peptidase and fpn gene encoding
C11 peptidase (fragipain). Potential link between C10
peptidase and the pathogenesis of inflammatory bowel
disease and sepsis has been documented and fragipain has
been shown to activate B. fragilis enterotoxin [17, 18].
The susceptibility of B. fragilis to metronidazole and
carbapenem has been excellent with few anecdotal re-
ports of resistance emerging in the literature over the
last 3 decades [19–21]. They have remained the drugs
extensively used for the treatment of infections caused
by this opportunistic pathogen. The emerging reports of
B. fragilis isolates resistant to these drugs are causing in-
creasing concern to the infectious diseases and clinical
microbiology experts worldwide. The trend of resistance
to these drugs by B. fragilis in our country, and
elsewhere in the Gulf countries, is not clearly defined at
molecular level.
This study was designed to investigate the prevalence
of ETBF and the bft genes among B. fragilis isolates col-
lected over 13 years in the Anaerobic Reference Labora-
tory and to determine the presence of genes mediating
carbapenemase (cfiA) production among carbapenem-
resistant B. fragilis isolates. It was also planned to investi-




A total of 421 B. fragilis isolates were collected from the
following different sources: wound infections (WIs),
lower respiratory tract infections (LRTIs), bloodstream
infections (BSIs), biopsy specimens, urine, and bile. As
shown in Table 1, out of the 421 isolates, 210 (49.9%)
harbored the bft gene. The majority of the bft-positive
isolates were from WIs, followed by LRTIs, BSIs and bi-
opsy specimens (BS).
The ages ranged from 1month to 94 years (mean,
52 years). Of the 210 patients, 137 (65.2%) were males
and 73 (34.8%) were females. Out of 39 isolates de-
rived from patients with BSIs, 20 (51.2%) were posi-
tive for bft gene. The presence of bfp1–4 (C 10
protease gene) and fpn (C11 protease gene) were in-
vestigated in the 210 bft-positive B. fragilis strains
using PCR. As shown in Table 2, the distribution of
C10 protease (bfp) genes was the following: 25
(11.9%) isolates harbored bfp-1 gene, 20 (9.5%) bfp-2
and 9 (4.2%) bfp-3 isotypes alone.
Of the 210, 59 (28.1%) strains carried both bfp-1 and
bfp-2 simultaneously, and 31 (14.7%) strains were posi-
tive for bfp-1, bfp-2 and bfp-3. In all, 46 (21.9%) isolates
did not carry any of the tested bfp genes.
As shown in Table 3, 170 (80%) B. fragilis were posi-
tive for fpn (C11 protease) gene among the 210 bft-posi-
tive strains, 34 (20%) of which were cfiA-positive.
Table 1 Distribution of B. fragilis bft subtypes among different
sources of infections
Sources Number (%) Total (%)
bft-1 bft-2 bft-3
Wound infection 105 (50) 16 (7.6) 5 (2.4) 126 (60)
Respiratory tract infection 30 (14.3) 11 (5.2) 0 41 (19.5)
Bloodstream infection 16 (7.6) 4 (1.9) 0 20 (9.5)
Biopsy 17 (8.1) 2 (1) 1 (0.5) 20 (9.5)
Urine 1 (0.5) 0 0 1 (0.5)
Bile 1 (0.5) 0 0 1 (0.5)
Unknown 1 (0.5) 0 0 1 (0.5)
Total 171 (81.4) 33 (15.7) 6 (2.9) 210 (100)
Jamal et al. BMC Microbiology           (2020) 20:14 Page 2 of 7
Antimicrobial susceptibility testing and distribution of
resistance cfiA gene
MIC range, MIC50 MIC90 and percentage of resistance
of the tested antibiotics are shown in Table 4.
A total of 261 (62%) and 257 (61.1%) were resistant to
clindamycin and piperacillin, respectively. Amoxicillin-
clavulanic acid and cefoxitin had unacceptable high MIC
values: 135 (32.1%) and 110 (26.1%) were resistant, re-
spectively. Resistance rates to metronidazole, tigecycline,
imipenem and meropenem were 4, 14, 11, and 17%, re-
spectively. When resistance rates among bft-positive and
bft-negative strains were compared, only resistance to
clindamycin and tigecycline were higher among bft-posi-
tive than the bft-negative strains but only resistance to
clindamycin attained statistically significant level (P =
0.048: CI 18.1–23.21) (Table 5).
Further analysis showed that 72 (34.2%) of bft-positive
isolates were multidrug resistant (MDR), that is non-
susceptibility to at least one agent in 3 or more different
antimicrobial categories [22]. Out of the 72 MDR iso-
lates, 64 (88.9%) and 8 (11.1%) were bft-1 and bft-2 sub-
types, respectively. None of the bft-3 positive strains was
multidrug-resistant.
Thirty-four (8.1%) and 19 (4.5%) of 421 isolates were
resistant to meropenem and imipenem, respectively.
Mechanism of carbapenem resistance revealed that all
the carbapenem resistant strains were positive for the
cfiA gene. This equates with 16.2% of the 210 bft-posi-
tive isolates. The sources of these resistant isolates were
WIs [23], biopsy samples [4], BSI [3] and LRTIs [3]. A
cfiA gene was detected in one B. fragilis strain that
showed susceptibility to both imipenem and meropenem
with MIC of 2 and 4 μg/ml, respectively. This isolate was
cultured from a patient with wound infection. In
addition, one B. fragilis isolate was resistant to both imi-
penem and meropenem with MIC of 8 and > 32 μg/ml,
respectively, but cfiA-negative.
Discussion
B. fragilis can cause serious clinical infections thought to
be related to the production of enterotoxin (bft), among
other virulence factors. This toxin is activated by C11
(fpn) and C10 proteases (bfp) which help in the invasive-
ness of the organism. It has been shown that bft-positive
B. fragilis are more invasive than bft-negative isolates in
different types of infections and that blood culture iso-
lates are more likely to carry bft enterotoxin gene than
other isolates [24]. The prevalence of 49.9% for the en-
terotoxin producing-extra intestinal B. fragilis in our
study is relatively high when compared with the figures
of 14.4% reported in Poland [25], 18.6%, in Japan [16],
6.2–38% in USA [6, 7], and 13–25% in Hungary [11, 26].
Our data showed that the majority (81.4%) of the isolates
contained bft-1 isotype compared with 15.7% of bft-2
and 2.9% bft-3 isotypes. It is pertinent to note that no
bft-4 isotype strain was detected in this series. This order
of prevalence of the isotypes is partially concordant with
previous reports by Scotto d’Abusco et al., [27], Sarvari
et al., [11] and Kierzkowska et al., [25]. In their study,
Sarvari and colleagues [11] from Hungary reported the
prevalence of 10% for the bft-1 isotype compared with
3% bft-2 but, unlike our study, they did not detect bft-3
isotype. This difference in the distribution of bft gene
may be related to the severity of illness, prior antimicro-
bial therapy, type of the diet and thus gut flora and the
method used to detect the enterotoxin. In addition,
more than half (51.2%) of the isolates from bloodstream
infections in Kuwait were enterotoxin producers which
was much higher than previous reports from the USA
and Japan (19–28.1% by Claros et al., 2006 and Kato
Table 2 Distribution of bfp genes among 210 bft-positive B.
fragilis strains
bfp gene in B. fragilis strains No (%)
bfp1- positive 25 (11.9)
bfp2-positive 20 (9.5)
bfp3-positive 9 (4.2)
bfp4 positive 0 (0)
bfp1 and bfp2-positive 59 (28.1)
bfp1 and bfp3-positive 8 (3.8)
bfp1 and bfp4-positive 1 (0.47)
bfp2 and bfp3-positive 3 (1.4)
bfp1, bfp2 and bfp3-positive 31 (14.7)
bfp1, bfp2 and bfp4-positive 2 (0.95)
bfp1, bfp2, bfp3 and bfp4-positive 6 (12.6)
bfp –negative 46 (21.9)
Table 3 Distribution of fpn and bfp1–4 genes in the cfiA-
positive and cfiA-negative B. fragilis




bfp1- positive (25) 11 14
bfp2- positive (20) 1 19
bfp3- positive (9) 0 9
bfp4- positive (0) 0 0
bfp1 and bfp2-positive (60) 12 48
bfp1 and bfp3-positive (8) 0 8
bfp1 and bfp4-positive (1) 0 1
bfp2 and bfp3-positive (3) 0 3
bfp1, bfp2 and bfp3-positive (31) 6 25
bfp1, bfp2, bfp4-positive (2) 2 0
bfp1, bfp2, bfp3 and bfp3-positive (6) 1 5
bft-negative isolates (46) 1 45
fpn-positive strains (170) 34 136
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et al, 1996, respectively) [16, 28]. In our study, simultan-
eous harboring of 2, 3 and 4 bfp isotypes occurred in 71,
33 and 6 isolates, respectively, which is higher than those
reported by Sarvari et al., and among the most bft-posi-
tive strains, bfp-1 was the most prevalent isotype. This
was discordant with the results of the study reported by
Sarvari et al., in which the most common isotype was
bfp-2 [11]. In addition, they did not find 4 isotypes in
the same isolates [11]. Almost half of our isolates were
bft-negative although they were pathogenic in a number
of clinical scenarios. The explanation for this may be
due to production of other virulence factors e.g. lipo-
polysaccharide (LPS) endotoxin especially after exposure
to antibiotics [13] or both LPS and capsule that act as
adhesion allowing the organism to become established at
the site of infection and providing a nidus for abscess
formation [1, 24].
The majority (60%) of bft-positive B. fragilis isolates
were from wound infections which was higher than that
reported from Germany and USA (10%; 24) and from
Hungary (51%; 11), but lower than that reported in
Warsaw, Poland (67.5%; 28). This probably implies that
bft-positive strains are more pathogenic in wound infec-
tions than the bft-negative strains.
Antimicrobial resistance is a growing problem all over
the world including resistance phenomena by B. fragilis.
In this study, resistance to clindamycin (62%) was at
an unacceptable level. This shows that B. fragilis in
Kuwait are much more highly resistant to this agent
than discordant reports elsewhere, such as 28.5% in
Europe [29], 48.9% in Taiwan [30], 29.9% in USA [31]
and 36.6% in China [32]. It is conceivable that the
over use and abuse of this agent in almost all govern-
ment and private hospitals as well as dental clinics in
Kuwait is responsible for the alarming high resistance
rate. Other relatively high unacceptable resistance
level of 26% was recorded against cefoxitin. This is
very disturbing finding as this agent is massively used
for surgical prophylaxis by most of our surgeons in
the country. Its empirical use must therefore be called
to question. Metronidazole was the most active non-
β-lactam drug with 4% resistance rate. Despite being
an active agent in our country, this resistance rate is
much higher than those reported from other coun-
tries around the world [29–32]. Although the resist-
ance rate to amoxicillin-clavulanic acid in our study
is marginally higher than those reported around the
globe, it is nonetheless at a very uncomfortable high
level (32%). Another very interesting but disturbing
finding, in our study, is the relatively high tigecycline
resistance level of 14%. This is too high when com-
pared with findings reported in the European study
Table 4 Antimicrobial susceptibility for 421 B. fragilis isolates
Antimicrobial agent (breakpoint in μg/ml) Range MIC50 MIC90 % of resistance
Amoxicillin-clavulanic acid (4) 0.125 - > 256 2 > 256 32
Clindamycin (2) < 0.016 - > 256 > 256 > 256 62
Imipenem (4) 0.023 - > 32 0.25 6 11
Meropenem (4) 0.023 - > 32 0.5 > 32 17
Metronidazole (8) 0.023 - > 256 1 2 4
Piperacillin (16) 0.19 - > 256 > 256 > 256 61
Cefoxitin (16) 0.032 - > 256 8 > 256 26
Tigecycline (4) 0.094–32 1 8 14
Table 5 Antimicrobial resistance among bft-positive (210) and bft-negative (211) B. fragilis









interval (CI)bft-1 bft-2 bft-3
Amoxicillin-clavulanic acid (4) 56 (26.7) 2 (1) 2 (1) 60 (28.8) 37 (34.6) 0.354230 [−15.52, 27.12]
Clindamycin (2) 119 (56.7) 20 (9.5) 3 (1.4) 142 (67.6) 120 (56.9) 0.048847 [− 1.81, 23.21]
Imipenem (4) 16 (7.6) 1 (0.5) 1 (0.5) 18 (8.6) 27 (12.8) 0.482089 [−18.50, 26.90]
Meropenem (4) 31 (14.8) 2 (1) 1 (0.5) 34 (16.2) 39 (18.5) 0.479721 [−17.83, 22.43]
Metronidazole (8) 10 (4.8) 2 (1) 0 12 (5.7) 6 (2.8) 0.182954 [− 28.21, 34.01]
Piperacillin (16) 102 (48.6) 15 (7.1) 4 (1.9) 121 (57.6) 136 (64.5) 0.157430 [− 5.81, 19.61]
Cefoxitin (16) 36 (17.1) 2 (1) 1 (0.5) 39 (18.6) 70 (33.2) 0.079984 [−3.85, 33.05]
Tigecycline (4) 29 (13.8) 5 (2.4) 3 (1.4) 37 (17.6) 21 (10) 0.345271 [−13.89, 29.09]
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(1.8%) by Nagy et al., [29], 0% in Taiwan study [30]
and 5.4% in USA study [31].
B. fragilis resistance to carbapenem is often associated
with production of a class B metallo-β- lactamase
encoded by the chromosomal cfiA gene, in addition to
outer membrane permeability barrier mechanism [33].
In our study, 11 and 17% of B. fragilis were resistant to
imipenem and meropenem, respectively which are much
higher than those reported in Europe (1.2% for imipenem)
[29], USA (1.1% for imipenem and 2.5% meropenem) [31],
Taiwan (8.5% imipenem and 9.9% meropenem) [30].
However, the B. fragilis resistance to imipenem and mero-
penem in our study were lower than reported in China
(22.7 and 18.2%, respectively) [32]. One of our B. fragilis
isolate was resistant to both imipenem and meropenem in
the absence of cfiA gene which was similar to the report
in studies by Soki et al., [34]. Our speculation is that this
may be due to other mechanism of resistance, perhaps out
membrane permeability problem. Detection of 16.2% cfiA
gene is higher than 1.8% which was reported in Poland
[25] but lower than that of 36.4% reported in China [32].
A cfiA gene was detected in one B. fragilis isolate that
showed susceptibility to both imipenem and meropenem.
This has been reported previously [35, 36] and can be ex-
plained by the absence of insertion sequence upstream the
gene leading to poor expression of cfiA gene.
Limitation of the study include retrospective collection
of isolates and clinical data. Response to therapy could
not be determined and insertion sequence elements were
not done in the cfiA-positive isolates. Although to our
knowledge the most common mechanism of carba-
penem resistance in B. fragilis is the production of cfiA
metallo-β-lactamase via activation of the cfiA gene by IS
elements (high level resistance) or by activation of its
putative own promoter other possible mechanisms, such
as other carbapenemase genes and AmpC gene, were
not investigated.
Conclusions
The prevalence of enterotoxin-producing B. fragilis
strains among the clinical isolates of extra-intestinal ori-
gin was very high in our study. There was no statistically
significance difference in the antibiotic resistance rates
among bft-positive and bft-negative isolates except for
clindamycin. In this study, metronidazole was the most




This was a multicenter prospective investigational study
of stored B. fragilis isolates from 6 hospital microbio-
logical laboratories (Mubarak, Amiri, Al Babtain, Ibn
Sina, Adan and Maternity hospitals) in Kuwait. All
clinical isolates obtained from proven cases of infections
stored at − 80 °C were resuscitated and viable strains in-
vestigated for enterotoxin production.
Bacterial strains
The bacterial strains were isolates collected during a 13-
years period, from 2006 through 2018, and stored in the
Anaerobe Reference Laboratory, Faculty of Medicine,
Kuwait University. The viable B. fragilis isolates were
from proven cases of intra-abdominal infections, lower
respiratory tract infections, bloodstream infections,
wound infections and abscesses, managed in the 6 hospi-
tals. All isolates were stored, in Brain Heart Infusion
(BHI, Oxoid limited, Basingstoke, Hampshire, UK) broth
containing 20% glycerol, at -80 °C. During our investiga-
tion, isolates were subcultured on Brucella blood agar
(Becton Dickinson, Heidelberg, Germany) incubated for
48 h at 37 °C, in an Anoxomat Anaerobic WS800
system™ (MART Microbiology BV, Lichtenvoorde,
Netherlands), in an atmospheric condition of 85%
N2, 10% CO2, 5% H2. The identification was confirmed by
a Matrix Assisted Laser Desorption/Ionization-Time of
Flight Mass Spectrometry (MALDI-TOF MS; bioMérieux,
L’Etoile, Marcy, France) analysis.
Antimicrobial susceptibility testing (AST)
The susceptibility of the isolates to 8 anti-anaerobic anti-
biotics was investigated by determining the minimum
inhibitory concentrations (MICs) of the antibiotics using
the E test method (bioMérieux) according to manufac-
turer’s instructions. The antibiotics tested were the follow-
ing: amoxicillin-clavulanic acid, clindamycin, cefoxitin,
imipenem, meropenem, metronidazole, piperacillin and
tigecycline. Susceptibility profiles of the isolates were de-
termined according to the interpretative criteria recom-
mended by the CLSI, 2018 [37]. B. fragilis ATCC 25285,
and B. thetaiotaomicron ATCC 29741 were included as
control in each run. Results for the isolates were accepted
if the quality control strains results were within the estab-
lished CLSI ranges (CLSI, 2018). MIC50, MIC90 and per-
centage of resistance were calculated.
Molecular detection of fragilysin (bft) gene
Using previously published procedure, a PCR was per-
formed for the detection of bft gene in all the B. fragilis
isolates using bftF and bftR primers [18]. The genes, pri-
mer sequences, cycling conditions are shown in Table 6.
The following positive controls were used: B. fragilis
R19811 (bft-1), B. fragilis 1 ATCC 43858 (bft-2), and B.
fragilis GAI 96462 (bft-3). Sequencing of the amplicons
of the internal fragments of bft-1, bft-2 and bft-3 were
performed using a GenAmp PCR system 9700 by cycling
sequencing with BigDye® Terminator (AB Applied Bio-
systems, Carlsbad, California, USA).
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Molecular detection of cfiA carbapenemase–producing gene
Production of carbapenemase by the isolates was de-
tected in selected number of strains with very high MIC
values for meropenem/imipenem using modified Hodge
test. All bft-positive strains as well as imipenem and/or
meropenem resistant B. fragilis (i.e. MIC ≥4 μg/ml) were
screened for the presence of cfiA gene and confirmed by
PCR, using published primers [38]. The genes, primer
sequences, cycling conditions are given in Table 6. PCR
was carried out in a volume of 25 μl. The PCR mix
was obtained from Qiagen (Hilden, Germany) and the
supernatant of boiled bacterial cells was used as a
source of DNA template and the concentration of
each primer was 25 pmol. PCR products was sepa-
rated by agarose gel electrophoresis and stained with
1% ethidium bromide (Bio-Rad, Hercules, CA, USA)
and visualized by UV light.
Molecular analysis of C10 protease (bfp1–4) and C11
protease (fragipain, fpn) genes
For all bft-positive isolates, bfp1–4 and fpn genes in the
C10 and C11 proteases, respectively, were investigated.
They were investigated by PCR using the genes, primer
sequences, cycling conditions given in Table 6 and the
following control strains: B. fragilis 638R (bfp1–4) and B.
fragilis ATCC 43859 (fpn) were included [17, 23, 28].
Statistical evaluation
The EpiCalc 2000, version 1.02 (Brixton Heath, Llanidloes,
Powys, Wales, UK) was used to compare two proportions-
percentages with 95% confidence interval and one sided
P-value.
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Table 6 The genes, primer sequence, cycling condition and reference for fragilysin bft gene, fpn, bfp1–4 genes and cfiA
carbapenemase gene
Gene Primer sequence (5′ to 3′) Cycling condition Product size (bp) Reference
bft bftF: CGAACTCGGTTTATGCAGTT
bftR: GGATACATCAGCTGGGTTGT
95 °C/5 min; followed by 35 cycles of 95 °C/45 s,




95 °C 5 min; followed by 35 cycles of 95 °C/45 s;




95 °C 10min; 35 cycles of 95 °C/15 s; 59 °C/30s;




95 °C 10min; 35 cycles of 95 °C/15 s; 59 °C/30 s;




95 °C 10min; 35 cycles of 95 °C/15 s; 59 °C/30 s;




95 °C 10min; 35 cycles of 95 °C/15 s; 59 °C/30s;




95 °C/10 min, followed by 35 cycles of 95 °C/15 s,
59 °C/30s, 72 °C/ 7 s; 72 °C/7 min
302 [38]
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